Federal contract award
FA460023F0086
MEDICAL COUNTERMEASURE DRUG DISCOVERY & DEVELOPMENT INCREMENT 3
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | FA4600 55 CONS PKP |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AC32 — NATIONAL DEFENSE R&D SERVICES; DEFENSE-RELATED ACTIVITIES; APPLIED RESEARCH |
| Parent award / vehicle | FA460020D0003 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $10.7M |
| Current contract value | $16.2M |
| Potential contract value / ceiling | $24.5M |
| Start date | Sep 1, 2023 |
| Current end date | Aug 31, 2026 |
| Potential end date | Aug 31, 2028 |
| Latest award activity | Apr 7, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 7, 2026 | P00005 | $0 | MEDICAL COUNTERMEASURE DRUG DISCOVERY AND DEVELOPMENT INCREMENT 3 SUPPORTING THE US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USA MRDC) AND THE DEFENSE HEALTH AGENCY (DCA) SEEKS TO PROVIDE THE UNITED STATES GOVERNMENT AND THE DEPARTMENT OF DEFEN |
| Aug 20, 2025 | P00004 | $1.3M | MEDICAL COUNTERMEASURE DRUG DISCOVERY AND DEVELOPMENT INCREMENT 3 SUPPORTING THE US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USA MRDC) AND THE DEFENSE HEALTH AGENCY (DCA) SEEKS TO PROVIDE THE UNITED STATES GOVERNMENT AND THE DEPARTMENT OF DEFEN |
| Jun 30, 2025 | P00003 | $0 | MEDICAL COUNTERMEASURE DRUG DISCOVERY AND DEVELOPMENT INCREMENT 3 SUPPORTING THE US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USA MRDC) AND THE DEFENSE HEALTH AGENCY (DCA) SEEKS TO PROVIDE THE UNITED STATES GOVERNMENT AND THE DEPARTMENT OF DEFEN |
| Aug 30, 2024 | P00002 | $6.3M | MEDICAL COUNTERMEASURE DRUG DISCOVERY AND DEVELOPMENT INCREMENT 3 SUPPORTING THE US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USA MRDC) AND THE DEFENSE HEALTH AGENCY (DCA) SEEKS TO PROVIDE THE UNITED STATES GOVERNMENT AND THE DEPARTMENT OF DEFEN |
| Jun 14, 2024 | P00001 | $0 | MEDICAL COUNTERMEASURE DRUG DISCOVERY AND DEVELOPMENT INCREMENT 3 SUPPORTING THE US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USA MRDC) AND THE DEFENSE HEALTH AGENCY (DCA) SEEKS TO PROVIDE THE UNITED STATES GOVERNMENT AND THE DEPARTMENT OF DEFEN |
| Aug 30, 2023 | 0 | $3.1M | MEDICAL COUNTERMEASURE DRUG DISCOVERY & DEVELOPMENT INCREMENT 3 |
Estimated positioning window
Aug 31, 2027 – Feb 29, 2028
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2028-08-31 (669 days from calculation)
- +25 points
- 6 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2026-04-07
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.